FML FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FML FORTE (FML FORTE).
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in suppression of inflammation, immune response, and fibroblast proliferation.
| Metabolism | Primarily metabolized in the liver via CYP3A4-mediated hydroxylation and reduction to inactive metabolites. |
| Excretion | Eliminated primarily via hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 60-70%, with about 30-40% excreted in feces via bile. |
| Half-life | Plasma terminal elimination half-life is approximately 3-4 hours (range 2-6 hours) for fluorometholone alcohol; clinical effects may persist longer due to tissue retention. |
| Protein binding | Fluorometholone is approximately 90-92% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Apparent volume of distribution is approximately 0.8-1.0 L/kg, indicating distribution into total body water with some tissue binding. |
| Bioavailability | Ophthalmic suspension: Systemic bioavailability is low (approximately 1-2%) after topical ocular administration due to limited absorption and first-pass metabolism. |
| Onset of Action | Topical ophthalmic administration: Onset of anti-inflammatory effect occurs within 1-2 hours after instillation. |
| Duration of Action | Topical ophthalmic: Duration of anti-inflammatory effect lasts approximately 12-24 hours after a single dose, supporting twice-daily dosing for most indications. |
| Molecular Weight | 376.46 |
1 drop of 0.25% ophthalmic suspension in the conjunctival sac of the affected eye(s) every 4 hours. In severe conditions, 1 drop every 2 hours initially, taper as response is achieved.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Safety and efficacy not established; use only if clearly needed and under specialist guidance. |
| Geriatric use | No specific dose adjustment; monitor intraocular pressure and cataract formation closely. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. Corticosteroids have been shown to be teratogenic in animals at low doses. Use only if potential benefit justifies potential risk to the fetus. |
| 2nd trimester | Same as T1. Prolonged use may lead to fetal growth restriction and adrenal suppression. Monitor for intrauterine growth restriction if used chronically. |
| 3rd trimester | Same as T1. Risk of neonatal adrenal suppression if used near term. Use with caution. |
Clinical note
Comprehensive clinical and safety monograph for FML FORTE (FML FORTE).
| Placental transfer | Corticosteroids cross the placenta. Fluorometholone is a potent corticosteroid with significant placental transfer observed in animal studies. Degree is dose-dependent. |
| Breastfeeding | Systemic corticosteroids appear in human milk and could cause growth suppression or interfere with endogenous corticosteroid production in nursing infants. Topical ophthalmic administration results in negligible systemic absorption, but caution is advised. Use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
Epithelial herpes simplex keratitis (dendritic keratitis)Vaccinia, varicella, and other viral diseases of the cornea and conjunctivaMycobacterial infection of the eyeFungal diseases of ocular structuresHypersensitivity to any component of the formulation
| Precautions | Prolonged use may lead to elevated intraocular pressure (IOP), glaucoma, optic nerve damage, and cataract formation., Increased risk of secondary ocular infections, including fungal infections; consider fungal keratitis in persistent corneal ulceration., May mask or exacerbate infections; use with caution in patients with active or history of herpes simplex keratitis., Perforation risk in patients with corneal thinning diseases., Not recommended for use in children under 2 years of age. |
| Food/Dietary | No known food interactions with ophthalmic fluorometholone acetate. Systemic absorption is minimal, so dietary restrictions are not required. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FML FORTE (fluorometholone 0.25%) is a corticosteroid. Systemic corticosteroids are associated with increased risk of cleft palate at first trimester exposure (odds ratio 3-4). Chronic high-dose use in second/third trimester may cause fetal adrenal suppression, intrauterine growth restriction, and oligohydramnios. Topical ophthalmic use has minimal systemic absorption (<1% of dose), but prolonged high-frequency use might pose theoretical risks. |
| Fetal Monitoring | Monitor intraocular pressure (IOP) monthly during prolonged use. For high-dose or extended therapy, assess fetal growth by ultrasound if there is systemic exposure concern. No specific fetal monitoring required for routine ophthalmic use. |
| Fertility Effects | No known effects on fertility with ophthalmic use. Systemic corticosteroids may alter menstrual cycles or spermatogenesis at high doses, but topical ocular use is unlikely to affect fertility. |
| Clinical Pearls | FML FORTE (fluorometholone acetate 0.1%) is a potent corticosteroid ophthalmic suspension with enhanced anti-inflammatory activity due to the acetate ester, which improves corneal penetration compared to fluorometholone alcohol. It is primarily indicated for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. Use with caution in patients with a history of herpes simplex keratitis; monitor for increased intraocular pressure (IOP), especially in known responders or glaucoma patients. Prolonged use may lead to posterior subcapsular cataract formation, secondary ocular infection, and delayed wound healing. Do not discontinue abruptly in chronic use; taper if used for extended periods. |
| Patient Advice | Shake the bottle well before each use to ensure the suspension is evenly mixed. · Wash hands thoroughly before applying the drops to avoid contamination. · Tilt your head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac. · Do not touch the dropper tip to any surface, including the eye, to prevent contamination. · Wait at least 5 minutes between applying different ophthalmic medications if using multiple drops. · Remove contact lenses before using and wait at least 15 minutes before reinserting. · Use exactly as prescribed; do not increase frequency or duration without consulting your doctor. · Report any vision changes, eye pain, increased redness, or discharge immediately. · Long-term use may increase eye pressure or cause cataracts; regular eye exams are necessary. · Do not share this medication with others. |